![]() |
Douglas Loe, Leede Jones Gable(5/11/22) |
||
|
|||
| |||
Steve Silver, Argus Research(4/13/22) |
|||
|
|||
|
![]() |
Douglas Loe, Managing Director & Analyst, Healthcare and Biotechnology – Leede Jones Gable |
Steve Silver, Outside IR – KCSA Strategic Communications | |
John Vandermosten, CFA – Zacks Small-Cap Research |
5/17/2022 – ProMIS Neurosciences presents at the 2022 Neuro4D International Conference
5/13/2022 – CORRECTION: ProMIS Neurosciences Announces First Quarter 2022 Results
5/13/2022 – ProMIS Holds Annual and Special Meeting of Shareholders All Resolutions Approved
5/3/2022 – Independent Proxy Advisory Firms, ISS and Glass Lewis, Recommend ProMIS Shareholders Vote FOR All Proposed Items at the Upcoming Annual and Special Meeting of Shareholders
4/28/2022 – ProMIS Neurosciences Reports New Milestones in Potential Therapeutic Approaches for Amyotrophic Lateral Sclerosis (ALS)
4/19/2022 – ProMIS appoints experienced industry veteran Larry Altstiel as Chief Medical Officer
4/7/2022 – ProMIS Neurosciences Presents at the 2022 American Academy of Neurology Annual Meeting
4/7/2022 – ProMIS Files Management Information Circular in Connection with Annual General and Special Meeting of Shareholders
3/24/2022 – ProMIS Neurosciences to Present at the 10th Annual Neurodegenerative Drug Development Summit
3/22/2022 – ProMIS Neurosciences Presents Preclinical Results of its Experimental Alzheimer's Vaccine at the 2022 International AD/PDTM Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders
3/17/2022 – ProMIS Neurosciences Announces Fiscal Year 2021 Results
3/10/2022 – ProMIS Neurosciences to Present at the 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PDTM) and Related Neurological Disorders
3/2/2022 – ProMIS Neurosciences' PMN310 antibody demonstrates significant cognitive benefit in a mouse model of Alzheimer's disease
The information provided above is from analysts, newsletters, the company and other contributors.
ProMIS Neurosciences Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.
The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.
The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here. Publications excerpted above may receive payment or sponsorship from the company mentioned.
Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
Readers should conduct their own research for all information publicly available concerning the company.
Alzheimer’s antibody therapy potentially “Best” of next generation | |
Highly selective antibody technology targets only misfolded (toxic) proteins | |
Proprietary discovery platform supports broad, rapidly expanding portfolio |
![]() Q2 2022 |
Start IND enabling studies for Parkinson’s and ALS lead candidates: H2 2022
|
![]() Q4 2022 |
PMN310 for Alzheimer’s: IND preparation complete Q4’2022
|
![]() Q1 2023 |
First clinical trial Q12023
|